Combination Inhibits Upstream and Downstream Targets in Oncogenic RAS Signaling Pathway, Offering Potential for Synergistic Anti-Tumor Benefit REVOLUTION Medicines, Inc., a clinical-stage oncology company focused on developing novel targeted therapies to inhibit...
CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Hannover Medical...
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has...
International Phase 1 clinical trials expected to start in 2019 In France, the studies will be conducted at Institut Curie and Toulouse-Oncopole Clinical trials co-funded by Transgene and its collaboration partner NEC Transgene (TNG.PA) (Euronext Paris: TNG), a...
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the first 30 subjects have been...
Email
Text